address1,city,zip,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToEbitda,52WeekChange,SandP52WeekChange,quoteType,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,regularMarketChangePercent,regularMarketPrice,marketState,corporateActions,regularMarketTime,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,market,esgPopulated,hasPrePostMarketData,firstTradeDateMilliseconds,shortName,cryptoTradeable,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,epsForward,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,longName,trailingPegRatio
ScheelevAegen 22,Lund,223 63,Sweden,46 46 19 20 00,https://www.activebiotech.com,Biotechnology,biotechnology,Biotechnology,Healthcare,healthcare,Healthcare,"Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.",5,"[{'maxAge': 1, 'name': 'Ms. Helen  Tuvesson Ph.D.', 'age': 62, 'title': 'President & CEO', 'yearBorn': 1962, 'fiscalYear': 2024, 'totalPay': 3883000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Hans  Kolam', 'age': 73, 'title': 'Chief Financial Officer', 'yearBorn': 1951, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Erik  Vahtola M.D., Ph.D.', 'age': 48, 'title': 'Chief Medical Officer', 'yearBorn': 1976, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}]",10,7,10,1,8,1748736000,1735603200,[],86400,4,0.1872,0.1876,0.1866,0.2275,0.1872,0.1876,0.1866,0.2275,0.0,1.524,40856727,40856727,33839248,8993572,8993572,0.217,0.22,0,0,270635200,0.063,0.529,0.184024,0.15077356,0.0,0.0,SEK,False,207401120,0.0,791438750,1230160000,0.40583,0.13384,1276160000,0.018,12.222222,1735603200,1767139200,1743379200,-39898000,-0.1,0.0,-5.354,-0.6336595,0.10500872,EQUITY,0.22,0.5,0.5,0.5,0.5,none,1,26200000,0.021,-38741000,1100000,2.883,2.874,5.069,-0.75488,-1.9089999,-24370750,-39015000,0.0,0.0,0.0,SEK,ACTI.ST,en-US,US,Equity,Delayed Quote,True,HIGH,17.52137,0.22,PREPRE,[],1751988575,STO,finmb_881966,Europe/Stockholm,CEST,7200000,se_market,False,False,1071820800000,Active Biotech AB,False,0.032800004,0.1866 - 0.2275,Stockholm,33839248,0.157,2.4920635,0.063 - 0.529,-0.309,-0.584121,-63.365948,1755757800,1755757800,1755757800,False,-0.1,0.0,0.035975993,0.19549619,0.069226444,0.45914182,15,0,Active Biotech AB (publ),
